Holen Sie sich die Stockscreener-App
137.23
0.09%
-0.12
Handel nachbörslich:
137.23
Schlusskurs vom Vortag:
$137.35
Offen:
$137.65
24-Stunden-Volumen:
598.52K
Relative Volume:
0.69
Marktkapitalisierung:
$13.61B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
46.52
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+0.17%
1M Leistung:
-3.27%
6M Leistung:
+44.62%
1J Leistung:
+17.85%
1-Tages-Spanne:
$135.78
$138.60
1-Wochen-Bereich:
$135.63
$140.53
52-Wochen-Spanne:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
137.23 | 13.62B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
143.46 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.80 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.17 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.61 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Can Neurocrine Biosciences Inc. stock maintain growth trajectoryWeekly Trade Recap & Real-Time Stock Movement Alerts - newser.com
What moving averages say about Neurocrine Biosciences Inc.Day Trade & Free Risk Controlled Daily Trade Plans - newser.com
Does the Recent Rare Earths News Move the Needle for Neurocrine Biosciences Valuation? - simplywall.st
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
United States Huntington's Disease Market is expected to reach - openPR.com
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionMarket Risk Analysis & Growth Focused Stock Reports - newser.com
Is Neurocrine Biosciences Inc a good long term investmentChart Pattern Recognition & Ride the Trends That Billionaires Follow - earlytimes.in
Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment - simplywall.st
Using data models to predict Neurocrine Biosciences Inc. stock movementOil Prices & Weekly Top Gainers Trade List - newser.com
Market reaction to Neurocrine Biosciences Inc.’s recent newsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
UBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Using economic indicators to assess Neurocrine Biosciences Inc. potential2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Neurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How to forecast Neurocrine Biosciences Inc. trends using time seriesJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Full technical analysis of Neurocrine Biosciences Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Neurocrine Bio. stock price target raised to $195 from $188 at UBS - Investing.com Nigeria
UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating - MarketScreener
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfoliosQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Neurocrine Biosciences publishes positive data from movement disorder study - MSN
RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener
Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - Eastern Progress
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc. - MarketBeat
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com
Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com
Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider
Neurocrine Demonstrates 77.8% PGI-C Response at 3 Years | NBIX Stock News - Stock Titan
Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com
What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st
Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com
What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com
Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail
Pure Financial Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):